With the Rise of eNeura’s Single-Pulse TMS (sTMS)
Pioneering a Revolution
Over the past four decades, Transcranial Magnetic Stimulation (TMS) has evolved from an experimental tool into a transformative therapeutic option in psychiatry and neurology. While repetitive TMS (rTMS) has become a mainstay in clinical practice, single-pulse TMS (sTMS), pioneered by eNeura, has brought the technology into patients’ homes—changing the way migraine and mental health are treated.
The history of TMS, the key milestones in clinical adoption, and the future opportunities ahead, including the role of portable, patient-directed therapies.
The Birth of TMS (early 1980s)
The story begins in the early 1980s, when British engineer Anthony Barker and colleagues created the first TMS device. Inspired by the foundational physics of H.C. Ørsted and Michael Faraday, this invention proved that magnetic fields could non-invasively stimulate the human brain. The earliest machines were limited in frequency, but they established the foundation for decades of research.
Expanding Clinical Possibilities (1985 – 1995)
During the late 1980s and early 1990s, researchers such as Mark George demonstrated that repetitive stimulation (rTMS) could improve mood in patients with depression. This period marked the shift of TMS from a neuroscience curiosity into a clinical candidate, particularly for psychiatric disorders.
Clinical Validation and Regulation (1995 – 2005)
By the late 1990s, TMS was entering clinical practice. First-generation devices gained regulatory clearances for diagnostic purposes, and companies like MagVenture began to build more accessible and reliable platforms. This decade laid the regulatory and clinical groundwork that would later enable broader psychiatric indications.
Evolving Techniques and Indications (2005 – 2015)
The 2000s and early 2010s saw rapid growth. Neuronetics achieved FDA clearance for the first rTMS system to treat major depressive disorder (2008), catalyzing adoption in psychiatry. Meanwhile, researchers explored new protocols for obsessive-compulsive disorder, chronic pain, and addiction.
eNeura enters the stage
In 2014, eNeura introduced SpringTMS®, the first FDA-cleared single-pulse TMS (sTMS) device for migraine treatment. Unlike rTMS delivered in clinics, sTMS was designed for patient-controlled, at-home use. This represented a paradigm shift—bringing neuromodulation out of the clinic and directly into patients’ daily lives.
The Present State (2015 – 2023)
Today, TMS is recognized globally as a safe, effective therapy. rTMS is established for depression and OCD, while clinical research expands into PTSD, bipolar disorder, and pain syndromes.
For migraine, eNeura’s SAVI Dual™ (FDA-cleared in 2019) advanced sTMS therapy, offering preventive and acute treatment options in a portable format. This made migraine neuromodulation accessible to thousands of patients worldwide, including those in the Veterans Affairs (VA) system.
The ability to treat from home not only reduced the burden of clinic visits but also opened the door to studying TMS in real-world, high-frequency use cases.
The Future of TMS (2024 – 2034)
The next decade promises both refinement and disruption across the TMS landscape:
- Accelerated Treatment Protocols
Clinical research is moving toward, intensive regimens that condense months of sTMS into just weeks—improving compliance and outcomes. - Precision Targeting
Integration of neuro-navigation and AI-based modeling will allow hyper-precise stimulation of brain networks, minimizing side effects while optimizing therapeutic benefit. - Personalized Medicine
Combining genetic data, neuroimaging, and digital biomarkers will enable tailoring of TMS to each patient’s neurobiology. - Expansion of sTMS and At-Home Care
eNeura’s pioneering work with portable single-pulse devices positions the industry to expand beyond clinic walls. At-home neuromodulation is expected to grow not only for migraine, but also for depression, PTSD, and potentially other neurological conditions.
Hybrid Clinical Models
Future pathways may combine in-clinic diagnostic sessions with ongoing at-home therapy, supported by cloud-connected devices that track usage and outcomes.
A Bright Future Ahead
From Anthony Barker’s laboratory in the 1980s to eNeura’s handheld migraine devices, TMS has continually evolved to meet the needs of patients and clinicians. The next decade will likely see an era where neuromodulation becomes as routine as pharmacology, with at-home TMS—led by single-pulse innovations—expanding access and redefining standards of care.
The story of TMS is not just about magnetic fields—it’s about transforming lives, one pulse at a time!
